These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6235245)

  • 1. Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.
    Levin RI; Harpel PC; Weil D; Chang TS; Rifkin DB
    J Clin Invest; 1984 Aug; 74(2):571-80. PubMed ID: 6235245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tissue plasminogen activator activity by aspirin in vivo and its relationship to levels of tissue plasminogen activator inhibitor antigen, plasminogen activator and their complexes.
    Levin RI; Harpel PC; Harpel JG; Recht PA
    Blood; 1989 Oct; 74(5):1635-43. PubMed ID: 2529003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin and venous occlusion: effects on blood fibrinolytic activity and tissue-type plasminogen activator levels.
    Hammouda MW; Moroz LA
    Thromb Res; 1986 Apr; 42(1):73-82. PubMed ID: 3085277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activation: biochemistry, physiology, and therapeutics.
    Wun TC
    Crit Rev Biotechnol; 1988; 8(2):131-48. PubMed ID: 2976309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.
    Reed GL; Matsueda GR; Haber E
    Proc Natl Acad Sci U S A; 1990 Feb; 87(3):1114-8. PubMed ID: 1689060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
    Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
    Agents Actions Suppl; 1992; 38 ( Pt 2)():320-9. PubMed ID: 1462839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation.
    Silverstein RL; Nachman RL; Leung LL; Harpel PC
    J Biol Chem; 1985 Aug; 260(18):10346-52. PubMed ID: 3160707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of ovulation rate by antibodies to tissue-type plasminogen activator and alpha 2-antiplasmin.
    Tsafriri A; Bicsak TA; Cajander SB; Ny T; Hsueh AJ
    Endocrinology; 1989 Jan; 124(1):415-21. PubMed ID: 2521207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-traumatic plasminogenesis in intraarticular exudate in the knee joint.
    Rość D; Powierza W; Zastawna E; Drewniak W; Michalski A; Kotschy M
    Med Sci Monit; 2002 May; 8(5):CR371-8. PubMed ID: 12011780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
    Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
    Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
    Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
    Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.